Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI by Haeck, J.C. (Joost) et al.
ORIGINAL RESEARCH Open Access
Imaging heterogeneity of peptide delivery
and binding in solid tumors using SPECT
imaging and MRI
J. C. Haeck1,2,3*†, K. Bol1,2,3†, C. M. A. de Ridder4, L. Brunel5, J. A. Fehrentz5, J. Martinez5, W. M. van Weerden4,
M. R. Bernsen1,3, M. de Jong1,3 and J. F. Veenland1,2
Abstract
Background: As model system, a solid-tumor patient-derived xenograft (PDX) model characterized by high peptide
receptor expression and histological tissue homogeneity was used to study radiopeptide targeting. In this solid-tumor
model, high tumor uptake of targeting peptides was expected. However, in vivo SPECT images showed substantial
heterogeneous radioactivity accumulation despite homogenous receptor distribution in the tumor xenografts as
assessed by in vitro autoradiography. We hypothesized that delivery of peptide to the tumor cells is dictated by
adequate local tumor perfusion. To study this relationship, sequential SPECT/CT and MRI were performed to assess the
role of vascular functionality in radiopeptide accumulation.
Methods: High-resolution SPECT and dynamic contrast-enhanced (DCE)-MRI were acquired in six mice bearing PC295
PDX tumors expressing the gastrin-releasing peptide (GRP) receptor. Two hours prior to SPECT imaging, animals received
25 MBq 111In(DOTA-(βAla)2-JMV594) (25 pmol). Images were acquired using multipinhole SPECT/CT. Directly after SPECT
imaging, MR images were acquired on a 7.0-T dedicated animal scanner. DCE-MR images were quantified using
semi-quantitative and quantitative models. The DCE-MR and SPECT images were spatially aligned to compute the
correlations between radioactivity and DCE-MRI-derived parameters over the tumor.
Results: Whereas histology, in vitro autoradiography, and multiple-weighted MRI scans all showed homogenous
tissue characteristics, both SPECT and DCE-MRI showed heterogeneous distribution patterns throughout the tumor.
The average Spearman’s correlation coefficient between SPECT and DCE-MRI ranged from 0.57 to 0.63 for the
“exchange-related” DCE-MRI perfusion parameters.
Conclusions: A positive correlation was shown between exchange-related DCE-MRI perfusion parameters and the
amount of radioactivity accumulated as measured by SPECT, demonstrating that vascular function was an important
aspect of radiopeptide distribution in solid tumors. The combined use of SPECT and MRI added crucial information on
the perfusion efficiency versus radiopeptide uptake in solid tumors and showed that functional tumor characteristics
varied locally even when the tissue appeared homogenous on current standard assessment techniques.
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Background
The discovery of cell-surface receptors overexpressed in
tumors has led to the development of tumor-targeting
radiopeptides for a variety of cancers. These radiopeptides
are being used for both diagnostic imaging and therapy-
response monitoring as well as for tumor-targeted ther-
apy. In order to be sensitive and effective, targeting should
be highly specific and distribution of the target should
ideally be homogenously distributed among the tumor
cells in both the primary and metastatic lesions.
However, heterogeneity of cancer is often present and a
well-known negative prognostic factor for therapy out-
come [1, 2]. Heterogeneous tumors tend to be more re-
sistant to therapy and more likely to have an aggressive
phenotype. Next to the routine study of morphologic tis-
sue appearance, it is also crucial to study functional tissue
properties, as heterogeneity in functional characteristics,
e.g., vasculature, are also prognostic markers. Current
clinical studies that use tumor-targeting radiolabeled pep-
tides are unable to explain potential variable responses to
be caused by the degree of homogenous or heterogeneous
intra-tumoral distribution of radiopeptides in patients as
nuclear imaging techniques do not have sufficient spatial
resolution [3, 4]. The influence of intra-tumoral peptide
heterogeneity on therapeutic efficacy has as yet not been
studied due to these spatial restrictions and remains an
important issue to investigate. Multi-modal imaging pro-
vides the opportunity to address this challenge.
Radiopeptides have been developed for imaging and
therapy and are being used in various cancer types, most
notably in neuroendocrine tumors and more recently also
in prostate and breast cancers [5–15]. Through coupling
of radionuclides to tumor-targeting peptides, the possibil-
ity arose to image these tumors using SPECT [11, 14, 16]
or PET [17] and treat the tumors by internal irradiation
using peptide receptor radionuclide therapy (PRRT). In
somatostatin receptor-overexpressing neuroendocrine tu-
mors, radiolabeled somatostatin analogs have shown to be
highly effective both in localizing primary and metastatic
tumors and in staging and treating these tumors [18, 19].
This approach is mimicked in prostate cancer and breast
cancer using bombesin analogs targeting the gastrin-
releasing peptide receptors (GRPr) with high affinity [11,
15, 16, 20, 21]. Improvements in therapeutic efficacy are
an important goal, which may be assisted by additional in-
formation on the intra-tumoral distribution of radiopep-
tides. In vivo molecular imaging constitutes an important
basis for research on tumor-targeting peptides and allows
for in-depth analysis of factors that play a crucial role in
successful tumor targeting. Previous preclinical imaging
studies raised questions concerning in vivo uptake pat-
terns. Despite high receptor expression and homogenous
receptor density in our model, assessed by biodistribution
and in vitro autoradiography [21], high-resolution in vivo
SPECT imaging revealed non-uniform uptake patterns of
radioactivity within tumor tissue [20, 22, 23]. Distribution
and accumulation of radiopeptides relies on several func-
tional characteristics of both tissue and peptide, such as
tissue vascularization and peptide ability to extravasate
from blood vessels, high binding affinity for the receptor,
and good retention in the tumor. The peptide analog ap-
plied in this study has earlier been shown to have high
specific affinity for the GRP receptor (Additional file 1:
Figure S1), so other factors contributed to the limited and
non-uniform tumor uptake seen in vivo [11, 15]. To further
identify tissue characteristics and tissue composition of
solid tumors that determine peptide distribution, MRI was
used as it allows for excellent soft tissue characterization.
Furthermore, weighted MR images can be tailored to be
sensitive to tissue characteristics by choosing the appropri-
ate imaging parameters, such as edema (T2 scan), necrosis
(T2 and T2* scans), and hemorrhages (T1, T2, and T2*
scans). Such tissue characteristics all lead to lower tissue
density or reduced functionality, which could potentially re-
veal tissue properties responsible for heterogeneous in vivo
peptide uptake. Moreover, MRI also allows investigation of
functional tumor characteristics by means of perfusion/per-
meability measurements using dynamic contrast-enhanced
(DCE)-MRI [24–27]. Since vascular properties of the tumor
play a role in delivery of radiopeptides to tumor tissue,
non-uniform peptide distribution patterns might be related
to vasculature function within the tumor. In a previous
study, we found a substantial correlation between radiola-
beled somatostatin analog uptake in tumors, as determined
by SPECT and DCE-MRI-derived tumor perfusion/perme-
ability parameters in a preclinical rat pancreatic-tumor
model expressing somatostatin receptors [22]. Tumor areas
with low DCE-MRI parameter values corresponded with
low peptide uptake.
In the current study, we used solid tumors from a pa-
tient-derived xenograft (PDX) of prostate cancer with high
expression of GRPr as a model system that appears
homogenous on histological H&E stains with high receptor
density throughout the tumor as detected by in vitro auto-
radiography, which led us to expect a high and homoge-
neous in vivo uptake throughout the tumor. Pilot imaging
experiments, however, showed this was not the case. Up-
take of radiopeptide highly specific for the GRP receptor,
as detected by SPECT, was compared to weighted MR im-
ages with various scanner settings and DCE-MRI perfusion




Male NMRI athymic nude mice (n = 6, Taconic M&B, RY,
Denmark), weighing approximately 30–35 g, were used.
PC295 tumor fragments were implanted subcutaneously
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in the right shoulder. To improve tumor take and growth,
mice were given subcutaneous testosterone implants. The
average largest diameter of the tumors was 14.1 ± 4 mm at
the time of imaging. During imaging, the animals were
anesthetized using isoflurane (Nicholas Piramal Limited,
London, UK). Body temperature was controlled using a
heated scan bed. To ensure the same position of the ani-
mal during both SPECT/CT and MRI imaging, animals
were placed in an animal holder compatible with both im-
aging modalities. After completion of the examinations,
animals were sacrificed and tumors were resected and fro-
zen for autoradiography and H&E staining. All animal ex-
periments described in this study were approved by the
Animal Experiments Committee under the Dutch Experi-
ments on Animal Act and adhered to the European Con-
vention for Protection of Vertebrate Animals used for
Experimental Purposes (Directive 86/609/EEC).
Radiolabeling
Radiolabeling of (DOTA-(βAla)2-JMV594) with indium-
111 was performed as described previously [11, 28]. In
short, 111InCl3 (Covidien, Petten, the Netherlands) was
added to a mixture of DOTA-JMV, quenchers, and sodium
acetate (final pH 4.0–4.5). Quenchers applied were ascor-
bic acid, (Sigma Aldrich, Zwijndrecht, the Netherlands),
gentisic acid (Covidien, Petten, the Netherlands), and me-
thionine (Sigma Aldrich, Zwijndrecht, the Netherlands).
The mixture was incubated for 20 min at 80 °C and cooled
to room temperature for 5 min prior to quality control.
Quality control was performed using HPLC as described
[28]. Specific radioactivity used in this study was 100 MBq/
nmol. Labeling efficiency was measured through ITLC and
was >95 % in all cases.
SPECT/CT imaging
Two hours prior to SPECT imaging, animals received
111In(DOTA-(βAla)2-JMV594) (25 MBq/25 pmol) in a
total volume of 100 μl in the tail vein. SPECT/CT images
were acquired using a four-head multipinhole NanoS-
PECT/CT camera (Bioscan, Mediso Medical Imaging Sys-
tems, Hungary). SPECT/CT images were acquired using
36 projections, 120 s/projection, and quality factor 1.
SPECT images were reconstructed using the OSEM
method, with six iterations and a voxel size of 0.4 × 0.4 ×
0.4 mm. CT images were acquired using the following set-
tings: 360 projections, 45 kVp tube voltage, 1000 ms ex-
posure time, a scan time of 9 min, and a voxel size of
0.2 × 0.2 × 0.2 mm. In a post-processing step, the CT im-
ages were resampled to the SPECT resolution.
MRI imaging
Directly after SPECT/CT imaging, MR images were ac-
quired. Imaging was performed on a 7.0-T dedicated ani-
mal scanner (Discovery MR901, Agilent Technologies/GE
Healthcare) using a four-channel surface receiver coil
(Rapid MR International, OH, USA) and a 150-mm trans-
mit body coil.
Several weighted images were acquired to study tumor
tissue composition. Five T1-weighted scans were acquired
using a spin echo sequence with varying repetition times
(TR) (200, 400, 800, 1200, and 2400 ms), echo time (TE) of
8.0 ms, 90° flip angle, a 5.0-cm field of view, and a voxel
size of 0.2 × 0.2 × 0.6 mm in order to calculate T1 value
from the saturation recovery curves [29]. The weighted T2
scan was obtained from the highest TR of the T1 map
(spin echo sequence, TR/TE = 2400/8 ms). High-resolution
T2* images were acquired using a gradient echo sequence,
TR 10 ms, TE 4.5 ms, 6° flip angle, field of view (FOV)
4 cm, and a voxel size of 0.098 × 0.098 × 0.30 mm. The T1
map was additionally used to calibrate the DCE data. The
T2* images were used for registration purposes.
Subsequently, DCE-MRI images were acquired. Gado-
butrol contrast agent (Gadovist, Bayer, Mijdrecht, the
Netherlands) was administered intravenously in a lateral
tail vein. A single bolus of 10 μl Gadovist was injected and
flushed with 150 μl injection fluid. In order to achieve high
temporal resolution, DCE-MRI images were acquired using
time-resolved imaging of contrast kinetics (TRICKS): 144
images were acquired with a temporal resolution of 4.7 s
each. These images were acquired in three sets of 48 im-
ages, 3.76 min each, with intervals of 60 and 120 s between
the respective acquisitions, and total measurement time
was 14 min. Other acquisition parameters for TRICKS in-
cluded TR 3.4 ms, TE 1.0 ms, 10° flip angle, FOV 5.0 cm,
and a voxel size of 0.2 × 0.2 × 0.6 mm.
Autoradiography and histology
After imaging, tumors were resected for in vitro autoradi-
ography analysis, by flash-freezing the tumors in liquid ni-
trogen. Tumors were sliced in 10-μm sections (Microm
Cryo-Star HM 560 M, Walldorf, Germany), mounted
on glass slides (Superfrost plus slides, Menzelgläser,
Braunschweig, Germany), and placed on a phosphor
screen (Packard Instruments Co., Meriden, CT, USA).
The phosphor screens were digitized after 24 h using the
OptiQuant 03.00 image processing system (PerkinElmer,
Groningen, the Netherlands). For in vitro autoradiography,
the tumor slices were stored at −80 ° C for 30 days to allow
for radioactive decay to eliminate background signal. Fro-
zen tumor sections were sliced in 5-μm sections, mounted
on glass, and incubated for 1 h with 111In(DOTA-(βAla)2-
JMV594) (100 MBq/nmol) at 37 °C. Excess radiolabel was
removed by a washing step, and the slides were placed
on a phosphor screen for 1 h. The screens were digi-
tized, and images were used to visually assess receptor
distribution. Adjacent slices to the autoradiography sec-
tions were stained with hematoxylin and eosin to study
the tissue structure.
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Data analysis
Registration of MRI with SPECT/CT
SPECT and CT images were aligned automatically by ded-
icated software in the SPECT/CT scanner. However, mis-
matches did occur, and additional manual alignment of
SPECT and CT images was performed in all cases. Manu-
ally, we aligned the centers of the tumor as seen on CT
and on SPECT so that all SPECT signals was contained
within the tumor. An example of a matched SPECT/CT
is depicted in the supplemental material (Additional file
2: Figure S2). The accuracy is limited to the SPECT
voxel level.
To enable spatial correlation between SPECT and MRI,
the high-resolution T2* images were registered to SPECT/
CT images. The tumors were manually delineated on both
the T2*and CT scans. Using these contours, tumor masks
were generated. The T2* masks were registered to the CT
masks using Elastix [30] applying subsequently a rigid and
an affine registration scheme. We registered the masks as
delineated on the CT and T2* datasets using a rigid and
affine registration scheme. We did not perform deform-
able registrations since the shapes of both masks were
very similar and since the information content within the
CT masks was very low. The transformation parameters
acquired from both registration schemes were then used
to transform the DCE-MRI images to the CT images.
DCE-MRI quantification
For calculation of DCE-MRI-derived parameters, a semi-
quantitative as well as a quantitative analysis method was
used. The analysis was performed using in-house devel-
oped software based on MATLAB (MathWorks, Natick,
MA, USA).
Semi-quantitative analysis
Signal-enhancement-over-time curves (SI-curves) were
constructed for all voxels inside the tumor mask. Six
semi-quantitative parameter maps were calculated dir-
ectly from the SI-curves: (1) maximum enhancement
(Smax), (2) time to peak (TTP), (3) area under the whole
curve (AUC), (4) area under the curve for the first 60 s
(AUC60), (5) wash-in (slope of the curve from the time
of injection to the first peak), and (6) wash-out. Since
the signal intensity in MRI is relative and can differ be-
tween subjects and scanners, semi-quantitative parame-
ters were normalized to pre-contrast levels, enabling
comparison between the different animals.
Quantitative analysis
To model the pharmacokinetic behavior of contrast agent
inside the tumor, the standard compartment model of
Tofts et al. [27] was used. The two parameters of interest
in this model are Ktrans and kep. K
trans is the capillary
transfer constant from the blood pool into tissue and is
influenced by blood flow and capillary permeability inside
the tumor. Its physiological interpretation therefore de-
pends on the balance between perfusion and permeability
[27]. kep is the contrast exchange rate from the extracellu-
lar extravascular space to the blood.
In order to calculate quantitative DCE-MRI parameters,
absolute MRI values are needed. For this purpose, T1(0)
maps were calculated from the five T1-weighted scans for
each animal. Based on all maps, a mean T1(0) value was
calculated from individual tumors and the averaged T1(0)
from the five mice was used to convert the SI-curves to
contrast-concentration curves. In addition, the Tofts
model requires an arterial input function (AIF), which was
taken from literature for nude mice [31]. We injected a
slightly higher amount of Gd-DOTA at a similar rate:
Weidensteiner: 0.1 mmol/kg at a rate of 0.05 ml/s and we
injected 0.3 mmol/kg at a rate of 0.04 ml/s. The compart-
ment model was then fitted to the contrast-concentration
curves using the standard Tofts equation, resulting in
parametric maps of Ktrans and kep.
Correlating DCE-MRI-derived parameters with SPECT
peptide uptake
We investigated the spatial correlation between radioactive
peptide uptake as measured with SPECT and DCE-MRI-
derived parameters using the Spearman’s rank correlation
coefficient. The correlations were calculated per mouse
dataset. The correlation was calculated for each tumor in-
dividually using all voxels within the tumor. The mean is
the average of the six individual correlation outcomes.
Only voxels within the tumor boundary were taken into
account, excluding the tumor-feeding vessels. However, as
shown by others [32], the standard-compartment Tofts
model sometimes poorly fits for voxels with low con-
trast enhancement. In these instances, kep has very
high, non-physiological values, which were seen to cor-
respond with little to no contrast accumulation on the
DCE-MR images. For these voxels, Ktrans and kep were
set to zero.
Results
The prostate cancer xenograft model PC295 was used as
a model system to assess the value of DCE-MRI-derived
parameters in studying the heterogeneous uptake of radi-
olabeled peptide 111In(DOTA-(βAla)2-JMV594)in tumor
tissue as imaged by SPECT.
In all PC295 tumors, in vitro autoradiography showed
a homogeneous receptor density throughout the tumor
and also on histology (H&E staining), homogenously vi-
able tissue was found without necrotic areas (Fig. 1
shows a representative example). In contrast, SPECT im-
ages showed a heterogeneous radioactivity distribution.
Figure 1 shows slices of approximately the same loca-
tion. As there is a difference in resolution/slice thickness
Haeck et al. EJNMMI Research  (2016) 6:3 Page 4 of 9
between the in vivo image and the sections, however, the
exact same location cannot be matched. We accom-
plished this by extruding the tumor and embedding it in
the same orientation as the MRI slices (axial) as accur-
ately as possible.
T1/T2 images of all PC295 tumors revealed a homoge-
neous tissue composition with no interfering factors
caused by edema (T2), necrosis (T2 and T2*), and hem-
orrhaging (T1, T2, and T2*). All images showed almost
uniform signal intensity throughout the tissue as illus-
trated for one tumor slice in Fig. 2a–c. This is in con-
cordance with the H&E results, where the cell-nuclei
staining shows the tissue properties in high resolution,
unachievable by MRI, whereas MRI was used for full-
coverage analysis of the tumor.
In contrast to the weighted images, DCE-MRI showed a
heterogeneous accumulation of contrast agent in most tu-
mors for the DCE-MRI-derived parameters AUC60 and
Ktrans (Fig. 2d–f ). Overlap (yellow) between SPECT pep-
tide uptake signal (green) and DCE-MRI AUC60 data
(red) is shown in Fig. 2g. In general, tumor areas with low
DCE-MRI values corresponded with low radioactivity,
while high DCE-MRI values corresponded with high
radioactivity.
To quantify the spatial correlation between radioactivity
and DCE-MRI parameters, the Spearman’s rank correl-
ation coefficient ρ (Table 1) was used, which calculates
how two variables relate to each other and the strength of
the relationship. The spearman coefficients are all moder-
ate to high showing a positive relationship between perfu-
sion of the tissue and the amount of radioactivity, with
some parameters showing a stronger correlation between
vascular functionality and radiopeptide targeting than
others. The DCE-MRI parameters AUC and Smax, repre-
sentative for contrast agent build-up, were shown to yield
a lower correlation with SPECT data than AUC60, wash-
in, Ktrans, and kep, representing the exchange of contrast
agent between tissue and blood. The wash-out and TTP
parameters showed lower correlations as compared to the
other “exchange-related” parameters.
Fig. 1 H&E staining of a PC295 tumor showing homogenous tissue density (a) and viable tissue as seen on an enlarged section (b). Single tumor
slice from SPECT image demonstrating heterogeneous peptide distribution in vivo (c) despite high and homogeneous receptor density throughout
the tumor as assessed by in vitro autoradiography (d)
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Discussion
In this study, we investigated several morphological and
functional characteristics of tumor tissue that are thought
to be related to uptake and distribution of tumor-targeting
radiopeptides in a solid-tumor model. Relevant tumor
features, such as tissue morphology, vascularization, and
functionality of tumor vasculature, were studied using
weighted MRI and DCE-MRI. The PC295 tumor used in
this study showed promising morphological characteris-
tics, with high tissue viability and high and homogenous
GRPr expression (Fig. 1d and Additional file 1: Figure S1),
leading to an expected high accumulation of the targeting
radiopeptide. In vivo high-resolution SPECT findings re-
vealed, however, that peptide binding was not consistent
in all areas of the tumor (Fig. 1, Additional file 2: Figure
S2). In vivo tissue characterization with MRI showed that
whereas the weighted images showed a homogeneous
tissue composition, parameters derived from DCE-MRI
correlated well with SPECT values, indicating the rele-
vance of functionality of the tumor vasculature in pep-
tide distribution.
Using a small molecular weight contrast agent, DCE-
MRI allows for visualization and quantification of the per-
fusion/vessel permeability of the tumor vessels. In contrast
to weighted MR images, DCE-MRI revealed heterogeneous
Fig. 2 Example of MRI and SPECT images and DCE-MRI parameters of a single tumor slice. a T1-weighted MRI. b T2-weighted MRI. c T2*-weighted
MRI. d Area under the curve for the first 60 s (AUC60). e Ktrans. f SPECT radiopeptide uptake. g Overlap (yellow) between AUC60 (red) and SPECT (green)
within the tumor boundary (dotted line)
Table 1 Means and standard deviations (SD) of Spearman’s
correlation coefficient (ρ) between SPECT radioactivity data
and various DCE-MRI parameters, calculated for 6 mice
DCE-MRI parameter Mean ρ (range) SD
AUC 0.29 (−0.21–0.52) 0.26
AUC60 0.57 (0.44–0.80) 0.12
Smax 0.40 (0.15–0.64) 0.16
TTP 0.43 (0.0–0.77) 0.26
Wash-in 0.55 (0.41–0.79) 0.14
Wash-out 0.33 (0.08–0.61) 0.22
Ktrans 0.60 (0.39–0.80) 0.14
kep 0.63 (0.47–0.79) 0.11
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vascular functionality in all tumor cases. Through voxel-
based registration of SPECT values and DCE-MRI-derived
parameters, a clear correlation between localized tissue
perfusion parameters and radioactivity accumulation in the
tumor could be established (Fig. 2). This was most appar-
ent in the exchange-related parameters AUC60, wash-in,
Ktrans, and kep for all datasets.
To the best of our knowledge, this is the first report
on the correlation between radiopeptide accumulation
in a patient-derived xenograft and DCE-MRI parame-
ters. This study used GRPr-targeted radiopeptides and
a GRPr-positive xenograft model as model systems, but
we assume that the results also apply to other (radio)-
peptides that target receptors highly expressed on solid
tumors. Our current findings are comparable with the re-
sults obtained in a syngeneic rat neuroendocrine tumor
model (CA290948) expressing high numbers of somato-
statin receptors but with extensive hemorrhaging and ne-
crosis as observed on histology [22]. In contrast, the
current prostate cancer xenograft model consisted of ra-
ther solid, slow growing, well-differentiated glandular tis-
sue, which may better reflect solid tumor features in
patients.
To study peptide distribution and accumulation in
solid tumors, we choose to study GRPr-targeting radio-
peptides that bind with high affinity to GRPr-expressing
tumor cells It has been shown in several prostate can-
cers and in PDX models of prostate cancer that the
GRPr expression is high [9, 11, 13, 20, 21]. The GRPr
antagonist (111In(DOTA-(βAla)2-JMV594)) was selected
as peptide as it has high receptor affinity and showed
prolonged attachment to the cell-surface receptor upon
binding [11].
Adequate delivery of peptide to the tumor is an im-
portant factor for successful tumor target. Such delivery
of peptides is dictated by a combination of the presence
of sufficient vasculature as well as of its functional prop-
erties, i.e., allowing extravasation from the blood pool to
the extravascular extracellular space. Extravasation is the
resultant of vascular perfusion and vessel permeability
characteristics and can be measured using DCE-MRI.
Histological staining of vessels, such as with CD31, could
further show the presence of vessels within the tumors
and could serve as validation of the relationship between
vascularity and radiopeptide accumulation in tumors.
Histology, however, cannot display the rate at which per-
fusion takes place, which the in vivo functional measure-
ments do. Additionally, intra-tumoral pressure also plays a
role in the exchange across the vessels and also contrib-
utes to the measured DCE-MRI parameters. These func-
tional perfusion/permeability properties of the vascular
bed in the tumor tissue can be measured over time using
a small molecular contrast agent. In a solid and histologi-
cally homogeneous tumor, tissue perfusion is expected to
be homogenous as well, as uniform tissue appearance sug-
gests homogenous delivery of nutrients and oxygen.
Clearly, functional imaging of the tumor vasculature re-
vealed that this is a simplified perception and that contrast
agent build-up in these tumors was not uniform in all areas
of the tumor. This lack of uniform vasculature function,
and consequently of radiopeptide distribution, was most
apparent in the exchange-related parameters (AUC60,
wash-in, Ktrans, and kep) for all datasets. The wash-out and
TTP parameters showed lower correlations as compared
to the other exchange-related parameters, such as AUC60,
Ktrans, and kep. We showed that the build-up of contrast
agent in the PC295 tumors was very slow, and in many
areas, little wash-out was visible at the end of the scanning
time, resulting in a poor correlation of wash-out and TTP
with SPECT uptake.
There are a number of factors that are challenging in
this multi-modal imaging approach. Registration be-
tween SPECT/CT and MRI is not a simple step, due to
small, but significant changes in animal position, even
though the animal was kept in the same position for the
different modalities using the same holder. SPECT and
CT images were aligned automatically by dedicated soft-
ware in the SPECT/CT scanner. The CT scan, which
was acquired along with the SPECT image, was used to
register SPECT/CT to MRI. However, visual inspection
of the registration between SPECT and CT revealed that
this automatic registration did not accurately register all
images; therefore, accurate manual registration was re-
quired in all cases.
There are several intrinsic factors that might affect the
correlation between SPECT and DCE-MRI-derived data,
which need to be taken into account. The pharmacody-
namic processes imaged by DCE-MRI and SPECT are dif-
ferent. The DCE-derived parameters are a measure of the
free exchange of contrast agent between the blood pool
and extravascular extracellular space, whereas with
SPECT, the accumulation of cell-surface receptor-bound
peptides is measured, a dynamic process that is not only
affected by peptide delivery via the vasculature but also
additionally by peptide receptor-binding affinity of the
cell-surface receptors. In addition, DCE-MRI and SPECT
measurements are acquired at different time points after
administration. SPECT images are acquired 2 h after in-
jection, whereas the DCE images are acquired during the
first 10 min of contrast injection. MRI-derived parameters
and SPECT uptake values are therefore not measuring the
same processes. Moreover, this SPECT peptide is larger
than the MRI contrast agent, but both are considered
small molecules (molecular weight 111In(DOTA-(βAla)2-J
MV594) conjugate—1641.90 [11], molecular weight Gado-
vist—604.7), and at this size considering the vessel charac-
teristics in tumors, the leakage characteristics are not
expected to differ greatly.
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Nevertheless, these data showed that DCE-MRI using
contrast agent to measure perfusion appeared to be a good
indicator for the ability of the radiopeptide to leak into the
targeted tissue. In areas with low DCE-MRI parameters, in-
dicating low perfusion, the radiopeptide seemed to have
poor ability to reach that region and, consequently, showed
poor uptake. Higher DCE-MRI parameter values corre-
lated with higher radiopeptide accumulation indicating that
good tissue perfusion and blood vessel permeability is es-
sential for peptide delivery into tumor tissue.
The high correlation coefficients of the peptide accumu-
lation (SPECT) and the DCE-MRI parameters AUC60,
wash-in, Ktrans, and kep further underscored the import-
ance of vascular extravasation and the relationship of local
tumor-vessel functionality with peptide delivery to the
cells. This result reveals the importance of establishing
perfusion and permeability properties of solid tumors
prior to radiopeptide-targeted interventions. In a patient
study, the tumor-vascular functionality measured by DCE-
MRI showed predictive value for PRRT treatment efficacy,
in which patients with large tumor areas of low perfusion
responded worse to therapy [33]. Improvements of tissue
perfusion or optimal timing of treatment at time points
with the highest DCE-MRI parameters could help to in-
crease overall tumor dose and consequently improved
PRRT efficacy. Better targeting efficiency could also allow
lower administered doses, which in turn can benefit pa-
tients concerning healthy organ toxicity [34–36].
Preclinical in vivo studies investigating tumor targeting
by high-affinity peptides are predominantly performed in
rats and mice using biodistribution data to quantify the
amount of radioactivity in the tumor. Yet, these studies
do not take into account the influence of tissue perfusion
of the respective peptide, which could lead to misinterpret-
ation of radiopeptide-targeting efficacy. Acquiring DCE-
MRI parameters for these tumors may help to better
interpret such radiopeptide uptake and biodistribution
results.
Conclusions
In conclusion, we have shown that peptide delivery and
accumulation in solid tumors as visualized by SPECT is
correlated to vascular extravasation and tumor-vessel
functionality as assessed by DCE-MRI parameters.
Despite differences in pharmacokinetic behavior of MRI
contrast agent and SPECT peptide, this study showed that
the perfusion/permeability characteristics as determined
with DCE-MRI can provide predictive information on the
ability of radiopeptides in reaching the targeted tissue [22].
The combined use of SPECT and MRI can therefore add
crucial information on the local perfusion efficiency in tu-
mors. We believe perfusion to be an essential and as yet an
underestimated factor in tumor uptake in peptide-targeted
imaging and therapy. It remains to be further investigated if
DCE-MRI-derived parameters may relate to PRRT efficacy.
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Additional files
Additional file 1: Figure S1. Autoradiography of PC295 xenograft
incubated with 10-9 M [111In]JMV4168. Left: homogenous GRPr expression
in PC295. Right: blocked section, showing specific uptake throughout the
whole tumor. 115In-labeled JMV was prepared by addition of a >5 times
mol ratio of 115In to the concentration of peptide in the reaction mixture.
After labeling, labeled peptides were injected into a HPLC. Chromatogram
at 278 nm showed base-to-base separation between labeled and non-labeled
DOTA-JMV4168. Duplicate cryostat sections (10 μm) of PC-295 xenograft
where incubated for 1 h with 10-9 M [111In]JMV4168, for blocked section with
addition of 1000× excess of cold labeled peptide. The receptors where
visualized by autoradiography using phosphor imaging screens and the
Cyclone phosphor imager, and data were analyzed using OptiQuant
software (Packard Instruments Co., Groningen, the Netherlands). [111In]JMV4168
uptake could be blocked almost completely with an excess of cold labeled
peptide, illustrating the specific binding of this compound. (TIF 276 kb)
Additional file 2: Figure S2. Cross section of a mouse bearing a
subcutaneous tumor. As can be seen, the tumor to background ratio is
high, and after 2 h, the blood pool is under the detection limit, visible in the
cross section of the heart. The figure additionally shows the high in vivo
resolution that allowed the analysis of all the areas with different amounts
of radiopeptide uptake levels. (TIF 165 kb)
Competing interests
All authors declare that he/she has no competing interests.
Authors’ contributions
JH and KB conceived the study, performed all the experiments and data
analysis, and equally contributed to the interpretation of the results, drafting,
and critically revising the manuscript. CR designed and performed the
animal handling setup and critically revised the manuscript. LB, JF, and JM
designed and produced the JMV peptide used for the study and helped to
critically revise the manuscript. WvW provided the mouse model,
participated in the study design and coordination, and helped to draft the
manuscript. MB, MdJ, and JV conceived the study, participated in its design
and coordination, and helped draft and critically revise the manuscript. All
authors read and approved the final submission.
Acknowledgements
This work was supported through the use of imaging equipment provided by
the Applied Molecular Imaging Erasmus MC (AMIE) facility and the financial
support from KWF. Additionally, we want to acknowledge Linda de Graaf for
the support in all areas of the experiment contributing to its success.
Funding
This study was funded under KWF grant “Erasmus MC R 2008-4037”.
Author details
1Department of Radiology, Erasmus MC, Rotterdam, the Netherlands.
2Department of Medical Informatics, Erasmus MC, Rotterdam, the Netherlands.
3Department of Nuclear Medicine, Erasmus MC, Dr. Molewaterplein 50, 3015 GE
Rotterdam, the Netherlands. 4Department of Urology, Erasmus MC, Rotterdam,
the Netherlands. 5IBMM, UMR 5247, CNRS, ENSCM, Faculté de Pharmacie,
Université Montpellier, Montpellier, France.
Received: 12 August 2015 Accepted: 5 January 2016
Haeck et al. EJNMMI Research  (2016) 6:3 Page 8 of 9
References
1. Mahrooghy M, Ashraf A, Days D, McDonald E, Rosen M, Mies C, et al.
Pharmacokinetic tumor heterogeneity as a prognostic biomarker for
classifying breast cancer recurrence risk. IEEE Trans Biomed Eng. 2015.
doi:10.1109/TBME.2015.2395812.
2. Soussan M, Orlhac F, Boubaya M, Zelek L, Ziol M, Eder V, et al. Relationship
between tumor heterogeneity measured on FDG-PET/CT and pathological
prognostic factors in invasive breast cancer. PLoS One. 2014;9:e94017. doi:
10.1371/journal.pone.0094017.
3. Kojima A, Matsumoto M, Takahashi M, Hirota Y, Yoshida H. Effect of spatial
resolution on SPECT quantification values. J Nucl Med. 1989;30:508–14.
4. Madsen MT. Recent advances in SPECT imaging. J Nucl Med. 2007;48:661–73.
5. Barve A, Jin W, Cheng K. Prostate cancer relevant antigens and enzymes for
targeted drug delivery. J Control Release. 2014. doi:10.1016/j.jconrel.2014.05.035.
6. Dimakakos A, Armakolas A, Koutsilieris M. Novel tools for prostate cancer
prognosis, diagnosis, and follow-up. Biomed Res Int. 2014;2014:890697.
doi:10.1155/2014/890697.
7. Giacchetti S, Gauville C, de Cremoux P, Bertin L, Berthon P, Abita JP, et al.
Characterization, in some human breast cancer cell lines, of gastrin-releasing
peptide-like receptors which are absent in normal breast epithelial cells. Int
J Cancer. 1990;46:293–8.
8. Ischia J, Patel O, Bolton D, Shulkes A, Baldwin GS. Expression and function
of gastrin-releasing peptide (GRP) in normal and cancerous urological
tissues. BJU Int. 2014;113 Suppl 2:40–7. doi:10.1111/bju.12594.
9. Maina T, Nock B, Mather S. Targeting prostate cancer with radiolabelled
bombesins. Cancer Imaging. 2006;6:153–7. doi:10.1102/1470-7330.2006.0025.
10. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human
prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152–9.
11. Marsouvanidis PJ, Nock BA, Hajjaj B, Fehrentz JA, Brunel L, M’Kadmi C, et al.
Gastrin releasing peptide receptor-directed radioligands based on a
bombesin antagonist: synthesis, (111)in-labeling, and preclinical profile.
J Med Chem. 2013;56:2374–84. doi:10.1021/jm301692p.
12. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast
cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur
J Nucl Med Mol Imaging. 2002;29:855–62. doi:10.1007/s00259-002-0794-5.
13. Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S,
Melis M, et al. Androgen-regulated gastrin-releasing peptide receptor
expression in androgen-dependent human prostate tumor xenografts. Int
J Cancer. 2010;126:2826–34. doi:10.1002/ijc.25000.
14. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M.
Peptide receptor imaging of prostate cancer with radiolabelled bombesin
analogues. Methods. 2009;48:200–4. doi:10.1016/j.ymeth.2009.04.002.
15. Dalm SU, Martens JW, Sieuwerts AM, van Deurzen CH, Koelewijn SJ, de Blois
E, et al. In vitro and in vivo application of radiolabeled gastrin-releasing
peptide receptor ligands in breast cancer. J Nucl Med. 2015;56:752–7. doi:10.
2967/jnumed.114.153023.
16. El-Gabry EA, Halpern EJ, Strup SE, Gomella LG. Imaging prostate cancer:
current and future applications. Oncology (Williston Park). 2001;15:325–36.
discussion 39-42.
17. Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de
Blois E, et al. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-
releasing peptide receptor antagonists for PET imaging of prostate cancer. J
Nucl Med. 2014;55:2050–6. doi:10.2967/jnumed.114.141143.
18. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion
JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-
DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319–25.
19. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij
PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-
DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:
2124–30. doi:10.1200/JCO.2007.15.2553.
20. Schroeder RP, Muller C, Reneman S, Melis ML, Breeman WA, de Blois E, et al.
A standardised study to compare prostate cancer targeting efficacy of five
radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging. 2010;37:
1386–96. doi:10.1007/s00259-010-1388-2.
21. de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning
EP, et al. Androgen-dependent expression of the gastrin-releasing peptide
receptor in human prostate tumor xenografts. J Nucl Med. 2007;48:88–93.
22. Bol K, Haeck JC, Groen HC, Niessen WJ, Bernsen MR, de Jong M, et al. Can
DCE-MRI explain the heterogeneity in radiopeptide uptake imaged by
SPECT in a pancreatic neuroendocrine tumor model? PLoS One. 2013;8:
e77076. doi:10.1371/journal.pone.0077076.
23. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA.
Selection of radiolabeled gastrin analogs for peptide receptor-targeted
radionuclide therapy. J Nucl Med. 2007;48:615–22.
24. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic
contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging.
2003;17:509–20. doi:10.1002/jmri.10304.
25. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current
status and future directions. J Magn Reson Imaging. 2002;16:407–22. doi:10.
1002/jmri.10176.
26. Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance
imaging in oncology: theory, data acquisition, analysis, and examples. Curr
Med Imaging Rev. 2009;3:91–107. doi:10.2174/157340507780619179.
27. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al.
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted
MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson
Imaging. 1999;10:223–32. doi:10.1002/(SICI)1522-2586(199909)10:3<223::
AID-JMRI2>3.0.CO;2-S.
28. de Blois E, Chan HS, Konijnenberg M, de Zanger R, Breeman WA. Effectiveness
of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-
containing regulatory peptides. Maintaining radiochemical purity as measured
by HPLC. Curr Top Med Chem. 2012;12:2677–85.
29. Tofts P. Quantitative MRI of the brain: measuring changes caused by
disease. John Wiley & Sons; 2005. ISBN: 0-470-84721-2.
30. Klein S, Staring M, Murphy K, Viergever MA, Pluim JP. Elastix: a toolbox for
intensity-based medical image registration. IEEE Trans Med Imaging. 2010;
29:196–205. doi:10.1109/TMI.2009.2035616.
31. Weidensteiner C, Rausch M, McSheehy PM, Allegrini PR. Quantitative
dynamic contrast-enhanced MRI in tumor-bearing rats and mice with
inversion recovery TrueFISP and two contrast agents at 4.7 T. J Magn Reson
Imaging. 2006;24:646–56. doi:10.1002/jmri.20676.
32. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic
contrast-enhanced T1-weighted MRI. Magn Reson Med. 2002;47:601–6.
33. Miyazaki K, Orton MR, Davidson RL, d’Arcy JA, Lewington V, Koh TS, et al.
Neuroendocrine tumor liver metastases: use of dynamic contrast-enhanced
MR imaging to monitor and predict radiolabeled octreotide therapy
response. Radiology. 2012;263:139–48. doi:10.1148/radiol.12110770.
34. Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C,
Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in
patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;
54:33–41. doi:10.2967/jnumed.112.107524.
35. Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose
distribution in human kidneys by octreotides in peptide receptor
radionuclide therapy. J Nucl Med. 2007;48:134–42.
36. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH,
et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with
[177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:
1138–46. doi:10.1007/s00259-009-1072-6.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Haeck et al. EJNMMI Research  (2016) 6:3 Page 9 of 9
